Suppr超能文献

经皮类固醇治疗慢性肌腱病的复发性疾病:一项初步研究。

Percutaneous steroidal treatment in relapses of chronic tendinopathies: a pilot study.

机构信息

Department of Human Movement Science, University of Chieti-Pescara, Chieti, Italy.

出版信息

Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):211-6. doi: 10.1177/039463201102400125.

Abstract

Relapses are frequently observed in subjects with chronic tendinopathies. Corticosteroid injections are usually performed with positive results, but are uncomfortable for the patient and not free from side effects. The aim of this pilot study is to evaluate the short-term efficacy and tolerability of an occlusive Betamethasone Valerate medicated Plaster (BMVP). Fifteen subjects with relapses of chronic tendinopathies (clinical and ultrasound diagnosis) were enrolled, and treated according to RICE (Rest - Ice - Compression - Elevation) protocol. An BMVP plaster was also applied on the affected tendon. Clinical examination, at baseline and after 7, 14, 21 and 28 days, included pain (VAS at rest and during activities) and functional evaluation. Local side effects on the area and drop-outs were also recorded. Pain, both at rest and during activities, significantly decreased at 28 days (from 3.7 ± 2.7 to 1.1 ± 1.7 p < 0.01, and from 7.3 ± 1.7 to 3.3 ± 1.4 p < 0.0000, respectively). Moreover, the patients reported a significant improvement in the functional limitation. Five subjects dropped out of the study. No side effects were reported. The release of the steroid in pharmacologically-active concentrations over 12 - 24 hours and the good penetration of the drug in subcutaneous tissues explain the positive results. BMVP application may be considered a reliable first therapeutic approach in relapses of chronic tendinopathies.

摘要

在患有慢性肌腱病的患者中,经常观察到疾病复发。皮质类固醇注射通常效果良好,但患者会感到不适,且并非没有副作用。本初步研究旨在评估封闭性倍他米松戊酸酯贴剂(BMVP)的短期疗效和耐受性。15 名患有慢性肌腱病(临床和超声诊断)复发的患者参与了研究,按照 RICE(休息-冰敷-加压-抬高)方案进行治疗。在受影响的肌腱上还应用了 BMVP 贴剂。临床检查在基线时以及 7、14、21 和 28 天时进行,包括疼痛(休息和活动时的 VAS)和功能评估。还记录了局部不良反应的区域和脱落情况。疼痛(无论是在休息时还是在活动时)在 28 天时明显减轻(从 3.7 ± 2.7 降至 1.1 ± 1.7,p < 0.01;从 7.3 ± 1.7 降至 3.3 ± 1.4,p < 0.0000)。此外,患者报告的功能受限显著改善。5 名患者退出了研究。没有报告任何副作用。皮质类固醇在 12-24 小时内以药理活性浓度释放,并且药物在皮下组织中有良好的渗透,这解释了治疗的积极效果。在慢性肌腱病的复发中,BMVP 的应用可被视为一种可靠的一线治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验